Explore more publications!
Oman Technology Reporter
Got News to Share?

Oman Technology Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oman Technology Reporter.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on November 7, 2025

E-Learning Market Size Reach USD 933.5 Billion Driving at 14.8% CAGR by 2032 Globally
Nov. 7, 2025

E-Learning Market Size Reach USD 933.5 Billion Driving at 14.8% CAGR by 2032 Globally

Indeterminate EIN Presswire
NEXTGEN DIGITAL CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT OF UNITS
Nov. 7, 2025

NEXTGEN DIGITAL CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT OF UNITS

Indeterminate GlobeNewswire
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
Nov. 7, 2025

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Indeterminate GlobeNewswire
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
Nov. 7, 2025

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

Indeterminate GlobeNewswire
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
Nov. 7, 2025

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Indeterminate GlobeNewswire
Rocket Doctor Grants RSUs and Stock Options
Nov. 7, 2025

Rocket Doctor Grants RSUs and Stock Options

Indeterminate GlobeNewswire
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
Nov. 7, 2025

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Indeterminate GlobeNewswire
Constellation Software Inc. Announces Results for the Third Quarter Ended September 30, 2025 and Declares Quarterly Dividend
Nov. 7, 2025

Constellation Software Inc. Announces Results for the Third Quarter Ended September 30, 2025 and Declares Quarterly Dividend

Indeterminate GlobeNewswire
CreditBlockchain Empowers BTC, ETH & DOGE Investors with AI-Driven Digital Asset Infrastructure
Nov. 7, 2025

CreditBlockchain Empowers BTC, ETH & DOGE Investors with AI-Driven Digital Asset Infrastructure

Indeterminate GlobeNewswire
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
Nov. 7, 2025

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Indeterminate GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Nov. 7, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov. 7, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov. 7, 2025

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

Indeterminate GlobeNewswire
TSplus Remote Support 4.3: Faster, Smarter, and More User-Friendly Than Ever
Nov. 7, 2025

TSplus Remote Support 4.3: Faster, Smarter, and More User-Friendly Than Ever

Indeterminate GlobeNewswire
BitMart Reframes Digital Asset Yield with the Launch of the Earn Overview Page
Nov. 7, 2025

BitMart Reframes Digital Asset Yield with the Launch of the Earn Overview Page

Indeterminate GlobeNewswire
Spyre Therapeutics Announces Grants of Inducement Awards
Nov. 7, 2025

Spyre Therapeutics Announces Grants of Inducement Awards

Indeterminate GlobeNewswire
Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov. 7, 2025

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Indeterminate GlobeNewswire
Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights
Nov. 7, 2025

Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights

Indeterminate GlobeNewswire
BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Nov. 7, 2025

BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Indeterminate GlobeNewswire
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
Nov. 7, 2025

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions